← 產業報告目錄
Cancer Immunotherapy Drugs Industry Research Report 2026
出版商 APO Research產業別 Healthcare & Life Sciences出版日期 2026-01-02頁數 142報告編號 APO-2d33727f6f
授權報價
| Single User | $2,950 USD |
| Multi User | $4,430 USD |
| Enterprise | $5,900 USD |
報告摘要
The global Cancer Immunotherapy Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Cancer Immunotherapy Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Cancer Immunotherapy Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
The Asia Pacific market for Cancer Immunotherapy Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Cancer Immunotherapy Drugs include Takeda, Johnson & Johnson, Novartis, Merck KGaA, Roche, Eli Lilly, Pfizer, GSK and Amgen, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Cancer Immunotherapy Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Cancer Immunotherapy Drugs Market by Company
Takeda
Johnson & Johnson
Novartis
Merck KGaA
Roche
Eli Lilly
Pfizer
GSK
Amgen
AbbVie
AstraZeneca
Seagen
Regeneron
Ono Pharmaceutical
Merck & Co
Innovent
Hengrui Medicine
Gilead Sciences
Exelixis
Bristol-Myers Squibb
Cancer Immunotherapy Drugs Segment by Type
CAR-T Cell Therapy
Cytokine-Based Immunotherapy
Immune Checkpoint Inhibitors
Other
Cancer Immunotherapy Drugs Segment by Application
Blood-related Cancer
Breast Cancer
Prostate Cancer
Lung Cancer
Other
Cancer Immunotherapy Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Immunotherapy Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cancer Immunotherapy Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Immunotherapy Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Cancer Immunotherapy Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Cancer Immunotherapy Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Cancer Immunotherapy Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
目錄 Table of Contents
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Cancer Immunotherapy Drugs Market Size (2021-2032)
2.2.2 Global Cancer Immunotherapy Drugs Sales (2021-2032)
2.2.3 Global Cancer Immunotherapy Drugs Market Average Price (2021-2032)
2.3 Cancer Immunotherapy Drugs by Type
2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
2.3.2 CAR-T Cell Therapy
2.3.3 Cytokine-Based Immunotherapy
2.3.4 Immune Checkpoint Inhibitors
2.3.5 Other
2.4 Cancer Immunotherapy Drugs by Application
2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
2.4.2 Blood-related Cancer
2.4.3 Breast Cancer
2.4.4 Prostate Cancer
2.4.5 Lung Cancer
2.4.6 Other
3 Market Competitive Landscape by Manufacturers
3.1 Global Cancer Immunotherapy Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
3.2 Global Cancer Immunotherapy Drugs Sales (K Units) of Manufacturers (2021-2026)
3.3 Global Cancer Immunotherapy Drugs Revenue of Manufacturers (2021-2026)
3.4 Global Cancer Immunotherapy Drugs Average Price by Manufacturers (2021-2026)
3.5 Global Cancer Immunotherapy Drugs Industry Ranking, 2024 VS 2025 VS 2026
3.6 Global Manufacturers of Cancer Immunotherapy Drugs, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Cancer Immunotherapy Drugs, Product Type & Application
3.8 Global Manufacturers of Cancer Immunotherapy Drugs, Established Date
3.9 Global Cancer Immunotherapy Drugs Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
4.1 Takeda
4.1.1 Takeda Company Information
4.1.2 Takeda Business Overview
4.1.3 Takeda Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
4.1.4 Takeda Cancer Immunotherapy Drugs Product Portfolio
4.1.5 Takeda Recent Developments
4.2 Johnson & Johnson
4.2.1 Johnson & Johnson Company Information
4.2.2 Johnson & Johnson Business Overview
4.2.3 Johnson & Johnson Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
4.2.4 Johnson & Johnson Cancer Immunotherapy Drugs Product Portfolio
4.2.5 Johnson & Johnson Recent Developments
4.3 Novartis
4.3.1 Novartis Company Information
4.3.2 Novartis Business Overview
4.3.3 Novartis Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
4.3.4 Novartis Cancer Immunotherapy Drugs Product Portfolio
4.3.5 Novartis Recent Developments
4.4 Merck KGaA
4.4.1 Merck KGaA Company Information
4.4.2 Merck KGaA Business Overview
4.4.3 Merck KGaA Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
4.4.4 Merck KGaA Cancer Immunotherapy Drugs Product Portfolio
4.4.5 Merck KGaA Recent Developments
4.5 Roche
4.5.1 Roche Company Information
4.5.2 Roche Business Overview
4.5.3 Roche Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
4.5.4 Roche Cancer Immunotherapy Drugs Product Portfolio
4.5.5 Roche Recent Developments
4.6 Eli Lilly
4.6.1 Eli Lilly Company Information
4.6.2 Eli Lilly Business Overview
4.6.3 Eli Lilly Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
4.6.4 Eli Lilly Cancer Immunotherapy Drugs Product Portfolio
4.6.5 Eli Lilly Recent Developments
4.7 Pfizer
4.7.1 Pfizer Company Information
4.7.2 Pfizer Business Overview
4.7.3 Pfizer Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
4.7.4 Pfizer Cancer Immunotherapy Drugs Product Portfolio
4.7.5 Pfizer Recent Developments
4.8 GSK
4.8.1 GSK Company Information
4.8.2 GSK Business Overview
4.8.3 GSK Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
4.8.4 GSK Cancer Immunotherapy Drugs Product Portfolio
4.8.5 GSK Recent Developments
4.9 Amgen
4.9.1 Amgen Company Information
4.9.2 Amgen Business Overview
4.9.3 Amgen Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
4.9.4 Amgen Cancer Immunotherapy Drugs Product Portfolio
4.9.5 Amgen Recent Developments
4.10 AbbVie
4.10.1 AbbVie Company Information
4.10.2 AbbVie Business Overview
4.10.3 AbbVie Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
4.10.4 AbbVie Cancer Immunotherapy Drugs Product Portfolio
4.10.5 AbbVie Recent Developments
4.11 AstraZeneca
4.11.1 AstraZeneca Company Information
4.11.2 AstraZeneca Business Overview
4.11.3 AstraZeneca Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
4.11.4 AstraZeneca Cancer Immunotherapy Drugs Product Portfolio
4.11.5 AstraZeneca Recent Developments
4.12 Seagen
4.12.1 Seagen Company Information
4.12.2 Seagen Business Overview
4.12.3 Seagen Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
4.12.4 Seagen Cancer Immunotherapy Drugs Product Portfolio
4.12.5 Seagen Recent Developments
4.13 Regeneron
4.13.1 Regeneron Company Information
4.13.2 Regeneron Business Overview
4.13.3 Regeneron Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
4.13.4 Regeneron Cancer Immunotherapy Drugs Product Portfolio
4.13.5 Regeneron Recent Developments
4.14 Ono Pharmaceutical
4.14.1 Ono Pharmaceutical Company Information
4.14.2 Ono Pharmaceutical Business Overview
4.14.3 Ono Pharmaceutical Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
4.14.4 Ono Pharmaceutical Cancer Immunotherapy Drugs Product Portfolio
4.14.5 Ono Pharmaceutical Recent Developments
4.15 Merck & Co
4.15.1 Merck & Co Company Information
4.15.2 Merck & Co Business Overview
4.15.3 Merck & Co Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
4.15.4 Merck & Co Cancer Immunotherapy Drugs Product Portfolio
4.15.5 Merck & Co Recent Developments
4.16 Innovent
4.16.1 Innovent Company Information
4.16.2 Innovent Business Overview
4.16.3 Innovent Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
4.16.4 Innovent Cancer Immunotherapy Drugs Product Portfolio
4.16.5 Innovent Recent Developments
4.17 Hengrui Medicine
4.17.1 Hengrui Medicine Company Information
4.17.2 Hengrui Medicine Business Overview
4.17.3 Hengrui Medicine Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
4.17.4 Hengrui Medicine Cancer Immunotherapy Drugs Product Portfolio
4.17.5 Hengrui Medicine Recent Developments
4.18 Gilead Sciences
4.18.1 Gilead Sciences Company Information
4.18.2 Gilead Sciences Business Overview
4.18.3 Gilead Sciences Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
4.18.4 Gilead Sciences Cancer Immunotherapy Drugs Product Portfolio
4.18.5 Gilead Sciences Recent Developments
4.19 Exelixis
4.19.1 Exelixis Company Information
4.19.2 Exelixis Business Overview
4.19.3 Exelixis Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
4.19.4 Exelixis Cancer Immunotherapy Drugs Product Portfolio
4.19.5 Exelixis Recent Developments
4.20 Bristol-Myers Squibb
4.20.1 Bristol-Myers Squibb Company Information
4.20.2 Bristol-Myers Squibb Business Overview
4.20.3 Bristol-Myers Squibb Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
4.20.4 Bristol-Myers Squibb Cancer Immunotherapy Drugs Product Portfolio
4.20.5 Bristol-Myers Squibb Recent Developments
5 Global Cancer Immunotherapy Drugs Market Scenario by Region
5.1 Global Cancer Immunotherapy Drugs Market Size by Region: 2021 VS 2025 VS 2032
5.2 Global Cancer Immunotherapy Drugs Sales by Region: 2021-2032
5.2.1 Global Cancer Immunotherapy Drugs Sales by Region: 2021-2026
5.2.2 Global Cancer Immunotherapy Drugs Sales by Region: 2027-2032
5.3 Global Cancer Immunotherapy Drugs Revenue by Region: 2021-2032
5.3.1 Global Cancer Immunotherapy Drugs Revenue by Region: 2021-2026
5.3.2 Global Cancer Immunotherapy Drugs Revenue by Region: 2027-2032
5.4 North America Cancer Immunotherapy Drugs Market Facts & Figures by Country
5.4.1 North America Cancer Immunotherapy Drugs Market Size by Country: 2021 VS 2025 VS 2032
5.4.2 North America Cancer Immunotherapy Drugs Sales by Country (2021-2032)
5.4.3 North America Cancer Immunotherapy Drugs Revenue by Country (2021-2032)
5.4.4 United States
5.4.5 Canada
5.5 Europe Cancer Immunotherapy Drugs Market Facts & Figures by Country
5.5.1 Europe Cancer Immunotherapy Drugs Market Size by Country: 2021 VS 2025 VS 2032
5.5.2 Europe Cancer Immunotherapy Drugs Sales by Country (2021-2032)
5.5.3 Europe Cancer Immunotherapy Drugs Revenue by Country (2021-2032)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Netherlands
5.5.9 Nordic Countries
5.6 Asia Pacific Cancer Immunotherapy Drugs Market Facts & Figures by Country
5.6.1 Asia Pacific Cancer Immunotherapy Drugs Market Size by Country: 2021 VS 2025 VS 2032
5.6.2 Asia Pacific Cancer Immunotherapy Drugs Sales by Country (2021-2032)
5.6.3 Asia Pacific Cancer Immunotherapy Drugs Revenue by Country (2021-2032)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 China Taiwan
5.6.10 Southeast Asia
5.7 South America Cancer Immunotherapy Drugs Market Facts & Figures by Country
5.7.1 South America Cancer Immunotherapy Drugs Market Size by Country: 2021 VS 2025 VS 2032
5.7.2 South America Cancer Immunotherapy Drugs Sales by Country (2021-2032)
5.7.3 South America Cancer Immunotherapy Drugs Revenue by Country (2021-2032)
5.7.4 Mexico
5.7.5 Brazil
5.7.6 Argentina
5.8 Middle East and Africa Cancer Immunotherapy Drugs Market Facts & Figures by Country
5.8.1 Middle East and Africa Cancer Immunotherapy Drugs Market Size by Country: 2021 VS 2025 VS 2032
5.8.2 Middle East and Africa Cancer Immunotherapy Drugs Sales by Country (2021-2032)
5.8.3 Middle East and Africa Cancer Immunotherapy Drugs Revenue by Country (2021-2032)
5.8.4 Turkey
5.8.5 Saudi Arabia
5.8.6 UAE
6 Segment by Type
6.1 Global Cancer Immunotherapy Drugs Sales by Type (2021-2032)
6.1.1 Global Cancer Immunotherapy Drugs Sales by Type (2021-2032) & (K Units)
6.1.2 Global Cancer Immunotherapy Drugs Sales Market Share by Type (2021-2032)
6.2 Global Cancer Immunotherapy Drugs Revenue by Type (2021-2032)
6.2.1 Global Cancer Immunotherapy Drugs Sales by Type (2021-2032) & (US$ Million)
6.2.2 Global Cancer Immunotherapy Drugs Revenue Market Share by Type (2021-2032)
6.3 Global Cancer Immunotherapy Drugs Price by Type (2021-2032)
7 Segment by Application
7.1 Global Cancer Immunotherapy Drugs Sales by Application (2021-2032)
7.1.1 Global Cancer Immunotherapy Drugs Sales by Application (2021-2032) & (K Units)
7.1.2 Global Cancer Immunotherapy Drugs Sales Market Share by Application (2021-2032)
7.2 Global Cancer Immunotherapy Drugs Revenue by Application (2021-2032)
7.2.1 Global Cancer Immunotherapy Drugs Sales by Application (2021-2032) & (US$ Million)
7.2.2 Global Cancer Immunotherapy Drugs Revenue Market Share by Application (2021-2032)
7.3 Global Cancer Immunotherapy Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
8.1 Cancer Immunotherapy Drugs Value Chain Analysis
8.1.1 Cancer Immunotherapy Drugs Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Cancer Immunotherapy Drugs Production Mode & Process
8.2 Cancer Immunotherapy Drugs Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Cancer Immunotherapy Drugs Distributors
8.2.3 Cancer Immunotherapy Drugs Customers
9 Global Cancer Immunotherapy Drugs Analyzing Market Dynamics
9.1 Cancer Immunotherapy Drugs Industry Trends
9.2 Cancer Immunotherapy Drugs Industry Drivers
9.3 Cancer Immunotherapy Drugs Industry Opportunities and Challenges
9.4 Cancer Immunotherapy Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
圖表清單 List of Tables & Figures
List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million)
Table 5. Global Cancer Immunotherapy Drugs Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025)
Table 6. Global Cancer Immunotherapy Drugs Sales (K Units) of Manufacturers (2021-2026)
Table 7. Global Cancer Immunotherapy Drugs Sales Market Share by Manufacturers (2021-2026)
Table 8. Global Cancer Immunotherapy Drugs Revenue of Manufacturers (2021-2026)
Table 9. Global Cancer Immunotherapy Drugs Revenue Share by Manufacturers (2021-2026)
Table 10. Global Market Cancer Immunotherapy Drugs Average Price (US$/Unit) of Manufacturers (2021-2026)
Table 11. Global Cancer Immunotherapy Drugs Industry Ranking, 2024 VS 2025 VS 2026
Table 12. Global Manufacturers of Cancer Immunotherapy Drugs, Manufacturing Sites & Headquarters
Table 13. Global Manufacturers of Cancer Immunotherapy Drugs, Product Type & Application
Table 14. Global Cancer Immunotherapy Drugs Manufacturers Established Date
Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 16. Global Cancer Immunotherapy Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans)
Table 18. Takeda Company Information
Table 19. Takeda Business Overview
Table 20. Takeda Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 21. Takeda Cancer Immunotherapy Drugs Product Portfolio
Table 22. Takeda Recent Developments
Table 23. Johnson & Johnson Company Information
Table 24. Johnson & Johnson Business Overview
Table 25. Johnson & Johnson Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 26. Johnson & Johnson Cancer Immunotherapy Drugs Product Portfolio
Table 27. Johnson & Johnson Recent Developments
Table 28. Novartis Company Information
Table 29. Novartis Business Overview
Table 30. Novartis Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 31. Novartis Cancer Immunotherapy Drugs Product Portfolio
Table 32. Novartis Recent Developments
Table 33. Merck KGaA Company Information
Table 34. Merck KGaA Business Overview
Table 35. Merck KGaA Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 36. Merck KGaA Cancer Immunotherapy Drugs Product Portfolio
Table 37. Merck KGaA Recent Developments
Table 38. Roche Company Information
Table 39. Roche Business Overview
Table 40. Roche Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 41. Roche Cancer Immunotherapy Drugs Product Portfolio
Table 42. Roche Recent Developments
Table 43. Eli Lilly Company Information
Table 44. Eli Lilly Business Overview
Table 45. Eli Lilly Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 46. Eli Lilly Cancer Immunotherapy Drugs Product Portfolio
Table 47. Eli Lilly Recent Developments
Table 48. Pfizer Company Information
Table 49. Pfizer Business Overview
Table 50. Pfizer Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 51. Pfizer Cancer Immunotherapy Drugs Product Portfolio
Table 52. Pfizer Recent Developments
Table 53. GSK Company Information
Table 54. GSK Business Overview
Table 55. GSK Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 56. GSK Cancer Immunotherapy Drugs Product Portfolio
Table 57. GSK Recent Developments
Table 58. Amgen Company Information
Table 59. Amgen Business Overview
Table 60. Amgen Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 61. Amgen Cancer Immunotherapy Drugs Product Portfolio
Table 62. Amgen Recent Developments
Table 63. AbbVie Company Information
Table 64. AbbVie Business Overview
Table 65. AbbVie Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 66. AbbVie Cancer Immunotherapy Drugs Product Portfolio
Table 67. AbbVie Recent Developments
Table 68. AstraZeneca Company Information
Table 69. AstraZeneca Business Overview
Table 70. AstraZeneca Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 71. AstraZeneca Cancer Immunotherapy Drugs Product Portfolio
Table 72. AstraZeneca Recent Developments
Table 73. Seagen Company Information
Table 74. Seagen Business Overview
Table 75. Seagen Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 76. Seagen Cancer Immunotherapy Drugs Product Portfolio
Table 77. Seagen Recent Developments
Table 78. Regeneron Company Information
Table 79. Regeneron Business Overview
Table 80. Regeneron Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 81. Regeneron Cancer Immunotherapy Drugs Product Portfolio
Table 82. Regeneron Recent Developments
Table 83. Ono Pharmaceutical Company Information
Table 84. Ono Pharmaceutical Business Overview
Table 85. Ono Pharmaceutical Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 86. Ono Pharmaceutical Cancer Immunotherapy Drugs Product Portfolio
Table 87. Ono Pharmaceutical Recent Developments
Table 88. Merck & Co Company Information
Table 89. Merck & Co Business Overview
Table 90. Merck & Co Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 91. Merck & Co Cancer Immunotherapy Drugs Product Portfolio
Table 92. Merck & Co Recent Developments
Table 93. Innovent Company Information
Table 94. Innovent Business Overview
Table 95. Innovent Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. Innovent Cancer Immunotherapy Drugs Product Portfolio
Table 97. Innovent Recent Developments
Table 98. Hengrui Medicine Company Information
Table 99. Hengrui Medicine Business Overview
Table 100. Hengrui Medicine Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. Hengrui Medicine Cancer Immunotherapy Drugs Product Portfolio
Table 102. Hengrui Medicine Recent Developments
Table 103. Gilead Sciences Company Information
Table 104. Gilead Sciences Business Overview
Table 105. Gilead Sciences Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 106. Gilead Sciences Cancer Immunotherapy Drugs Product Portfolio
Table 107. Gilead Sciences Recent Developments
Table 108. Exelixis Company Information
Table 109. Exelixis Business Overview
Table 110. Exelixis Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 111. Exelixis Cancer Immunotherapy Drugs Product Portfolio
Table 112. Exelixis Recent Developments
Table 113. Bristol-Myers Squibb Company Information
Table 114. Bristol-Myers Squibb Business Overview
Table 115. Bristol-Myers Squibb Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 116. Bristol-Myers Squibb Cancer Immunotherapy Drugs Product Portfolio
Table 117. Bristol-Myers Squibb Recent Developments
Table 118. Global Cancer Immunotherapy Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032
Table 119. Global Cancer Immunotherapy Drugs Sales by Region (2021-2026) & (K Units)
Table 120. Global Cancer Immunotherapy Drugs Sales Market Share by Region (2021-2026)
Table 121. Global Cancer Immunotherapy Drugs Sales by Region (2027-2032) & (K Units)
Table 122. Global Cancer Immunotherapy Drugs Sales Market Share by Region (2027-2032)
Table 123. Global Cancer Immunotherapy Drugs Revenue by Region (2021-2026) & (US$ Million)
Table 124. Global Cancer Immunotherapy Drugs Revenue Market Share by Region (2021-2026)
Table 125. Global Cancer Immunotherapy Drugs Revenue by Region (2027-2032) & (US$ Million)
Table 126. Global Cancer Immunotherapy Drugs Revenue Market Share by Region (2027-2032)
Table 127. North America Cancer Immunotherapy Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 128. North America Cancer Immunotherapy Drugs Sales by Country (2021-2026) & (K Units)
Table 129. North America Cancer Immunotherapy Drugs Sales by Country (2027-2032) & (K Units)
Table 130. North America Cancer Immunotherapy Drugs Revenue by Country (2021-2026) & (US$ Million)
Table 131. North America Cancer Immunotherapy Drugs Revenue by Country (2027-2032) & (US$ Million)
Table 132. Europe Cancer Immunotherapy Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 133. Europe Cancer Immunotherapy Drugs Sales by Country (2021-2026) & (K Units)
Table 134. Europe Cancer Immunotherapy Drugs Sales by Country (2027-2032) & (K Units)
Table 135. Europe Cancer Immunotherapy Drugs Revenue by Country (2021-2026) & (US$ Million)
Table 136. Europe Cancer Immunotherapy Drugs Revenue by Country (2027-2032) & (US$ Million)
Table 137. Asia Pacific Cancer Immunotherapy Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 138. Asia Pacific Cancer Immunotherapy Drugs Sales by Country (2021-2026) & (K Units)
Table 139. Asia Pacific Cancer Immunotherapy Drugs Sales by Country (2027-2032) & (K Units)
Table 140. Asia Pacific Cancer Immunotherapy Drugs Revenue by Country (2021-2026) & (US$ Million)
Table 141. Asia Pacific Cancer Immunotherapy Drugs Revenue by Country (2027-2032) & (US$ Million)
Table 142. South America Cancer Immunotherapy Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 143. South America Cancer Immunotherapy Drugs Sales by Country (2021-2026) & (K Units)
Table 144. South America Cancer Immunotherapy Drugs Sales by Country (2027-2032) & (K Units)
Table 145. South America Cancer Immunotherapy Drugs Revenue by Country (2021-2026) & (US$ Million)
Table 146. South America Cancer Immunotherapy Drugs Revenue by Country (2027-2032) & (US$ Million)
Table 147. Middle East and Africa Cancer Immunotherapy Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 148. Middle East and Africa Cancer Immunotherapy Drugs Sales by Country (2021-2026) & (K Units)
Table 149. Middle East and Africa Cancer Immunotherapy Drugs Sales by Country (2027-2032) & (K Units)
Table 150. Middle East and Africa Cancer Immunotherapy Drugs Revenue by Country (2021-2026) & (US$ Million)
Table 151. Middle East and Africa Cancer Immunotherapy Drugs Revenue by Country (2027-2032) & (US$ Million)
Table 152. Global Cancer Immunotherapy Drugs Sales by Type (2021-2026) & (K Units)
Table 153. Global Cancer Immunotherapy Drugs Sales by Type (2027-2032) & (K Units)
Table 154. Global Cancer Immunotherapy Drugs Sales Market Share by Type (2021-2026)
Table 155. Global Cancer Immunotherapy Drugs Sales Market Share by Type (2027-2032)
Table 156. Global Cancer Immunotherapy Drugs Revenue by Type (2021-2026) & (US$ Million)
Table 157. Global Cancer Immunotherapy Drugs Revenue by Type (2027-2032) & (US$ Million)
Table 158. Global Cancer Immunotherapy Drugs Revenue Market Share by Type (2021-2026)
Table 159. Global Cancer Immunotherapy Drugs Revenue Market Share by Type (2027-2032)
Table 160. Global Cancer Immunotherapy Drugs Price by Type (2021-2026) & (US$/Unit)
Table 161. Global Cancer Immunotherapy Drugs Price by Type (2027-2032) & (US$/Unit)
Table 162. Global Cancer Immunotherapy Drugs Sales by Application (2021-2026) & (K Units)
Table 163. Global Cancer Immunotherapy Drugs Sales by Application (2027-2032) & (K Units)
Table 164. Global Cancer Immunotherapy Drugs Sales Market Share by Application (2021-2026)
Table 165. Global Cancer Immunotherapy Drugs Sales Market Share by Application (2027-2032)
Table 166. Global Cancer Immunotherapy Drugs Revenue by Application (2021-2026) & (US$ Million)
Table 167. Global Cancer Immunotherapy Drugs Revenue by Application (2027-2032) & (US$ Million)
Table 168. Global Cancer Immunotherapy Drugs Revenue Market Share by Application (2021-2026)
Table 169. Global Cancer Immunotherapy Drugs Revenue Market Share by Application (2027-2032)
Table 170. Global Cancer Immunotherapy Drugs Price by Application (2021-2026) & (US$/Unit)
Table 171. Global Cancer Immunotherapy Drugs Price by Application (2027-2032) & (US$/Unit)
Table 172. Key Raw Materials
Table 173. Raw Materials Key Suppliers
Table 174. Cancer Immunotherapy Drugs Distributors List
Table 175. Cancer Immunotherapy Drugs Customers List
Table 176. Cancer Immunotherapy Drugs Industry Trends
Table 177. Cancer Immunotherapy Drugs Industry Drivers
Table 178. Cancer Immunotherapy Drugs Industry Restraints
Table 179. Authors List of This Report
List of Figures
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Cancer Immunotherapy Drugs Product Image
Figure 5. Global Cancer Immunotherapy Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032
Figure 6. Global Cancer Immunotherapy Drugs Market Size (2021-2032) & (US$ Million)
Figure 7. Global Cancer Immunotherapy Drugs Sales (2021-2032) & (K Units)
Figure 8. Global Cancer Immunotherapy Drugs Average Price (US$/Unit) & (2021-2032)
Figure 9. CAR-T Cell Therapy Product Image
Figure 10. Cytokine-Based Immunotherapy Product Image
Figure 11. Immune Checkpoint Inhibitors Product Image
Figure 12. Other Product Image
Figure 13. Blood-related Cancer Product Image
Figure 14. Breast Cancer Product Image
Figure 15. Prostate Cancer Product Image
Figure 16. Lung Cancer Product Image
Figure 17. Other Product Image
Figure 18. Global Cancer Immunotherapy Drugs Revenue Share by Manufacturers in 2025
Figure 19. Global Manufacturers of Cancer Immunotherapy Drugs, Manufacturing Sites & Headquarters
Figure 20. Global Top 5 and 10 Cancer Immunotherapy Drugs Players Market Share by Revenue in 2025
Figure 21. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 22. Global Cancer Immunotherapy Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032
Figure 23. Global Cancer Immunotherapy Drugs Sales by Region in 2025
Figure 24. Global Cancer Immunotherapy Drugs Revenue by Region in 2025
Figure 25. North America Cancer Immunotherapy Drugs Market Size by Country in 2025
Figure 26. North America Cancer Immunotherapy Drugs Sales Market Share by Country (2021-2032)
Figure 27. North America Cancer Immunotherapy Drugs Revenue Market Share by Country (2021-2032)
Figure 28. United States Cancer Immunotherapy Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 29. Canada Cancer Immunotherapy Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 30. Europe Cancer Immunotherapy Drugs Market Size by Country in 2025
Figure 31. Europe Cancer Immunotherapy Drugs Sales Market Share by Country (2021-2032)
Figure 32. Europe Cancer Immunotherapy Drugs Revenue Market Share by Country (2021-2032)
Figure 33. Germany Cancer Immunotherapy Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 34. France Cancer Immunotherapy Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 35. U.K. Cancer Immunotherapy Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 36. Italy Cancer Immunotherapy Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 37. Netherlands Cancer Immunotherapy Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 38. Nordic Countries Cancer Immunotherapy Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 39. Asia Pacific Cancer Immunotherapy Drugs Market Size by Country in 2025
Figure 40. Asia Pacific Cancer Immunotherapy Drugs Sales Market Share by Country (2021-2032)
Figure 41. Asia Pacific Cancer Immunotherapy Drugs Revenue Market Share by Country (2021-2032)
Figure 42. China Cancer Immunotherapy Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 43. Japan Cancer Immunotherapy Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 44. South Korea Cancer Immunotherapy Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 45. India Cancer Immunotherapy Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 46. Australia Cancer Immunotherapy Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 47. China Taiwan Cancer Immunotherapy Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 48. Southeast Asia Cancer Immunotherapy Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 49. Southeast Asia Cancer Immunotherapy Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 50. South America Cancer Immunotherapy Drugs Market Size by Country in 2025
Figure 51. South America Cancer Immunotherapy Drugs Sales Market Share by Country (2021-2032)
Figure 52. South America Cancer Immunotherapy Drugs Revenue Market Share by Country (2021-2032)
Figure 53. Mexico Cancer Immunotherapy Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 54. Brazil Cancer Immunotherapy Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 55. Argentina Cancer Immunotherapy Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 56. Middle East and Africa Cancer Immunotherapy Drugs Market Size by Country in 2025
Figure 57. Middle East and Africa Cancer Immunotherapy Drugs Sales Market Share by Country (2021-2032)
Figure 58. Middle East and Africa Cancer Immunotherapy Drugs Revenue Market Share by Country (2021-2032)
Figure 59. Turkey Cancer Immunotherapy Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 60. Saudi Arabia Cancer Immunotherapy Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 61. UAE Cancer Immunotherapy Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 62. Global Cancer Immunotherapy Drugs Sales Market Share by Type (2021-2032)
Figure 63. Global Cancer Immunotherapy Drugs Revenue Market Share by Type (2021-2032)
Figure 64. Global Cancer Immunotherapy Drugs Price (US$/Unit) by Type (2021-2032)
Figure 65. Global Cancer Immunotherapy Drugs Sales Market Share by Application (2021-2032)
Figure 66. Global Cancer Immunotherapy Drugs Revenue Market Share by Application (2021-2032)
Figure 67. Global Cancer Immunotherapy Drugs Price (US$/Unit) by Application (2021-2032)
Figure 68. Cancer Immunotherapy Drugs Value Chain
Figure 69. Cancer Immunotherapy Drugs Production Mode & Process
Figure 70. Direct Comparison with Distribution Share
Figure 71. Distributors Profiles
Figure 72. Cancer Immunotherapy Drugs Industry Opportunities and Challenges
提及公司
TakedaJohnson & JohnsonNovartisMerck KGaARocheEli LillyPfizerGSKAmgenAbbVieAstraZenecaSeagenRegeneronOno PharmaceuticalMerck & CoInnoventHengrui MedicineGilead SciencesExelixisBristol-Myers Squibb
量子訊息有限公司為 APO Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們